about
High-grade glioma management and response assessment-recent advances and current challengesTherapeutic Use of Native and Recombinant EnterovirusesOncolytic virus therapy for glioblastoma multiforme: concepts and candidatesViruses as nanomedicine for cancerVstm3 is a member of the CD28 family and an important modulator of T-cell functionPermissiveness of human cancer cells to oncolytic bovine herpesvirus 1 is mediated in part by KRAS activityRecombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype.Oncolytic viruses: From bench to bedside with a focus on safety.Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiformeOncolytic polio virotherapy of cancerAttenuation of herpes simplex virus neurovirulence with picornavirus cis-acting genetic elements.Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacyGene therapy for malignant glioma.Attenuation of neurovirulence, biodistribution, and shedding of a poliovirus:rhinovirus chimera after intrathalamic inoculation in Macaca fascicularis.The Effect of Vector Silencing during Picornavirus Vaccination against Experimental Melanoma and GliomaNectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma.Polio, still lurking in the shadows.Prognostic significance of CD155 mRNA expression in soft tissue sarcomasEmerging immunotherapies for glioblastomaMolecular strategies for the treatment of malignant glioma--genes, viruses, and vaccines.Evaluation of IRES-mediated, cell-type-specific cytotoxicity of poliovirus using a colorimetric cell proliferation assay.Gene therapy for high-grade glioma: current approaches and future directions.Oncolytic viral therapy of malignant gliomaPerturbed CD8+ T cell TIGIT/CD226/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals.Evolution of oncolytic viruses: novel strategies for cancer treatment.Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer.Cytotoxic and immunogenic mechanisms of recombinant oncolytic poliovirusOncolytic immunotherapy through tumor-specific translation and cytotoxicity of poliovirus.Oncolytic viruses: a new class of immunotherapy drugs.Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas.Oncolytic poliovirus against malignant glioma.Sensitivity of C6 Glioma Cells Carrying the Human Poliovirus Receptor to Oncolytic Polioviruses.Oncolytic Virotherapy for the Treatment of Malignant Glioma.Immune and viral therapies for malignant primary brain tumors.The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Glioma-Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses.Intranodal interaction with dendritic cells dynamically regulates surface expression of the co-stimulatory receptor CD226 protein on murine T cells.Cell-type-specific repression of internal ribosome entry site activity by double-stranded RNA-binding protein 76.An oncolytic parasite to treat polycythemia vera.Viruses in the treatment of malignant glioma.Advances in the mechanisms of action of cancer-targeting oncolytic viruses.
P2860
Q26740664-B565716A-A73B-4AEC-9401-EDF89C01CDD7Q26767082-887A39E4-6D1A-4F81-B642-1683FC3AE155Q27007519-8807CE3F-D5A5-45D5-A9BC-35601510FFA0Q27690636-EB299368-17A7-40E3-844A-58A936FFADFFQ28512622-C7FC3963-2FFA-4331-BDB0-0AEB57BC2655Q33743847-98213E06-2DB9-41AE-BDC6-BBB4C186A1C9Q33797119-21352283-5293-49E9-9F79-1FF7B68E7E6BQ34044071-BA1B1251-EEE9-4051-9FFE-6F70274049ECQ34105106-E1BAB231-13B1-40F2-8A7D-A7152C502AE2Q34425385-83120F8B-03AD-4EB0-862F-0282C7CA74B6Q35635064-ED56B660-F622-4CB1-8180-474C8C03B2CAQ35657822-16A83AB0-8D0A-4FA2-91E8-83A9C6545644Q35673628-21796947-D1C6-4235-8E8E-C92B74E3628CQ35826143-8A995794-EECA-4597-8E37-05C553EE82C4Q36112877-B31A3929-588F-40A2-8672-C20F6E657C5FQ36339260-CC91B462-3DB0-4FE1-8E3E-B02699A94503Q36787462-D1DF5A5F-CC17-4C88-B883-11033E6FA6B9Q36981148-A7F28297-F997-4093-9F83-ED2882A8D8ADQ37025105-383501F0-94E6-4ABB-A8BB-69E3C4949E34Q37079854-750A6256-2C19-45B4-8FDF-C5B6BA39FC1DQ37116439-3250B065-1D6C-46E5-858A-66BC70A1F8C9Q37406685-180A872B-AE47-48AA-8761-CA5415E401C1Q37533665-D33F0BE1-6E13-4EA6-83B6-6FD2B0826F07Q37584487-AB84C5CF-546A-4DEF-BAD6-A419D70EB98BQ38159802-2939938E-03D6-403C-A83C-8BB88A81899AQ38223419-74D3ECA6-B8E9-45D7-806C-F68D8005D2CEQ38530234-E4E4F4AC-8593-4FD7-B279-C1AC5A3D3E05Q38536420-602D1058-053A-4550-A07A-74DF083D9806Q38577450-AA52C988-384E-47AE-BC7D-DB95A0911E4EQ38614523-F937D783-5405-49E7-B5CB-A88EADC6D3B9Q38636508-06B9E056-9020-4847-A196-C1B05A8B7A2EQ38736703-4F201460-792D-4EF2-852A-C26366835034Q38749871-F4E97354-70CA-43CD-8671-D1B35F206573Q39168899-44A10A53-E6F3-4DC7-ADE3-4F21DB7F17F9Q39294814-C8352BCD-E0B6-4FBF-8EFD-E75C1064D481Q39706525-2BE35C52-9346-4ABA-96C9-6787A1B30350Q40305040-09CDEC75-0496-45FB-ABDB-A7D41603AA07Q42614690-7046A996-7F30-4A4E-91F1-13FE93108125Q48209572-B947AC12-20D5-4D26-9858-2C44141A90B7Q52655195-55B39D39-E6E3-44A2-880B-B66030AA0446
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Poliovirus receptor CD155-targeted oncolysis of glioma
@ast
Poliovirus receptor CD155-targeted oncolysis of glioma
@en
type
label
Poliovirus receptor CD155-targeted oncolysis of glioma
@ast
Poliovirus receptor CD155-targeted oncolysis of glioma
@en
prefLabel
Poliovirus receptor CD155-targeted oncolysis of glioma
@ast
Poliovirus receptor CD155-targeted oncolysis of glioma
@en
P2093
P2860
P1433
P1476
Poliovirus receptor CD155-targeted oncolysis of glioma
@en
P2093
Carol J Wikstrand
Darell D Bigner
Matthias Gromeier
Melinda K Merrill
P2860
P304
P356
10.1215/S1152851703000577
P577
2004-07-01T00:00:00Z